Insight

Sep 10, 2024, 07:24

Vivek Subbiah: Precision medicine and tumor-agnostic therapies are leading the conversation at the ESMO24

Vivek Subbiah shared on LinkedIn:

“Countdown starts…Exciting News! Precision medicine and tumor-agnostic therapies are leading the conversation at the ESMO – European Society for Medical Oncology Annual meeting in Barcelona, Spain.

Delighted to announce that I’ve been invited to speak at the prestigious ESMO and American Society of Clinical Oncology (ASCO) joint session – on ‘Tumour-agnostic, biomarker-driven drug development: How and how often?’

This special session, co-chaired by the esteemed ESMO President Dr. Andres Cervantes and the remarkable ASCO President Dr. Robin Zon promises to be an unmissable event.

Join us for an in-depth meeting on ‘Novel Pathways for Development of Precision Therapeutics in Molecular Oncology.’

Date: Sunday, September 15, 2024
Time: 10:15 – 11:45 AM
Location: Oviedo Auditorium – Hall 3

Our amazing Dr. Julie Gralow, Chief Medical Officer American Society of Clinical Oncology will be talking on “Regulatory sandboxes: How to synchronize safe, timely regulation with scientific breakthroughs in molecular ‘niches’ ”

Mark your calendars and see you there!”

Vivek Subbiah

Source: Vivek Subbiah/LinkedIn

More posts featuring Vivek Subbiah on oncodaily.com

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.